The invention concerns the use of cells capable of carrying out a process
of prenylation of proteins coded by the hepatitis C virus (HCV) genome,
such as prenylation of the NS5A protein, for replicating and, if
required, the production of HCV or derivative viable mutants, in a
suitable culture medium.